Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor ("TKI”) being jointly developed and commercialized by AstraZeneca and HUTCHMED. In 2023, savolitinib and TAGRISSO ® ...

Scientists found that aggressive lung cancer cells create their own electrical network, helping them spread. This unique ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Panelists discuss treatment decision-making for metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, ...

A York County business owner is sharing his story of hope after completing an innovative cancer treatment at WellSpan York Hospital. John Grim has been battling prostate cancer for nearly seven ...

RNA vaccines were first developed years ago to target cancers and now they're really starting to show promise.

A troubling trend has emerged: some medical professionals appear alongside celebrities to endorse health supplements that ...

Bristol Myers (BMY)’ treatment of small cell lung cancer, atigotatug plus nivolumab fixed dose combination, received FDA ...

After being used since the 1940s in various industries, asbestos is now linked to severe health risks, including asbestosis, ...

In the continuing evolution of personalized medicine, a new study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with ...

A first-of-its-kind artificial intelligence (AI)-based neural network can rapidly analyze and interpret millions of cells from a patient sample, predicting molecular changes in the tissue.

Discover how diet affects lung cancer risk. Learn about the link between a high-fat, high-sugar diet and lung cancer ...